Expertise in
23
conditions

Dr. Asit Paul

Hematology | Oncology
Mcv Associated Physicians
1001 E Leigh St, 
Richmond, VA 
Offers Telehealth
Expertise in
23
conditions
Mcv Associated Physicians
1001 E Leigh St, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Asit Paul is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Paul is highly rated in 23 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), Bone Marrow Aspiration, and Nephrectomy.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Community Memorial Hospital
Medical College Of Virginia Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MCV ASSOCIATED PHYSICIANS
1001 E Leigh St, Richmond, VA 23298

Additional Areas of Focus

Dr. Paul has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Docetaxel
Study Phase: Phase 2
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drugs: Cediranib, Olaparib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other
Study Phase: Phase 3
View 8 Less Clinical Trials

26 Total Publications

HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer.
HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Similar Doctors
Expertise in
44
conditions
Dr. Andrew Poklepovic
Hematology | Oncology
Expertise in
44
conditions
Dr. Andrew Poklepovic
Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (0.1 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Poklepovic is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Poklepovic is highly rated in 44 conditions, according to our data. His top areas of expertise are Melanoma, Angiosarcoma, Merkel Cell Carcinoma, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

Expertise in
34
conditions
Dr. John C. Barrett
Hematology | Oncology
Expertise in
34
conditions
Dr. John C. Barrett
Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (0.1 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Barrett is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Barrett is highly rated in 34 conditions, according to our data. His top areas of expertise are Hemophilia A, Hemophilia B, Hemophilic Arthropathy, Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Barrett is currently accepting new patients.

Expertise in
26
conditions
Dr. John M. Mccarty
Oncology | Hematology | Transplant Surgery
Expertise in
26
conditions
Dr. John M. Mccarty
Oncology | Hematology | Transplant Surgery

Mcv Associated Physicians

1300 E Marshall St, 
Richmond, VA 
 (2.0 miles away)
804-828-0450
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

John Mccarty is an Oncologist and a Hematologist in Richmond, Virginia. Dr. Mccarty is highly rated in 26 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy. Dr. Mccarty is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Paul's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 105 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile